Brief: Rafael Pharmaceuticals Announces Ongoing Successful Enrollment And Opening Of Additional Sites For Phase 2 Clinical Trial Of Cpi-613®
18/01/2022 13:52
Jan 18 (Reuters) - Rafael Holdings Inc RFL.N :
* RAFAEL PHARMACEUTICALS ANNOUNCES ONGOING SUCCESSFUL
ENROLLMENT
AND OPENING OF ADDITIONAL SITES FOR PHASE 2 CLINICAL TRIAL OF
CPI-613® (DEVIMISTAT) IN COMBINATION WITH GEMCITABINE AND
CISPLATIN IN PATIENTS WITH BILIARY TRACT CANCER
Source text for Eikon: ID:nGNX7Fw9My
Further company coverage: RFL.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rafael Holdings
See all newsBrief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million